Volume 16, Issue 4 (winter 2009)
JSSU 2009, 16(4): 92-99 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Owlia M, Mehrpoor G. Rituximab in Adult –Onset Still’s Disease: Case Report. JSSU 2009; 16 (4) :92-99
URL: http://jssu.ssu.ac.ir/article-1-610-en.html
URL: http://jssu.ssu.ac.ir/article-1-610-en.html
Abstract: (8869 Views)
Summary: Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. It is characterized by high grade fever, skin rash, arthritis, leukocytosis, increased ESR, CRP and liver enzyme levels and high levels of ferritin.
The treatment of AOSD includes NSAIDs, steroids, and disease-modifying antirheumatic drugs (DMARDs). Recently biologic agents have been used for treatment of some rheumatologic disorders. Rituximab(MabThera), an anti-CD20 monoclonal antibody is one of the biologic agents which is used by only a few researchers for treatment of refractory AOSD. Herein, we describe a 23 year old woman, who was treated with Rituximab ,three years after diagnosis of AOSD .She did not respond to Metotroxate and Cellcept .After administration of Rituximab, clinical and laboratory remission was achieved .
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
